Technology Acquisition Strategies in the Pharmaceutical Industry in Mexico

2007 ◽  
Vol 5 (3) ◽  
pp. 274-296 ◽  
Author(s):  
María Pluvia. Zuñiga ◽  
Alenka. Guzmán ◽  
Flor. Brown Grossman
2017 ◽  
Vol 55 (6) ◽  
pp. 1163-1181 ◽  
Author(s):  
Federico Caviggioli ◽  
Antonio De Marco ◽  
Giuseppe Scellato ◽  
Elisa Ughetto

Purpose The purpose of this paper is to examine, for a sample of ten corporations in three industries (i.e. automotive suppliers, semiconductors, and computer networks), the different strategies that firms undertake when acquiring patent-protected technologies. In particular, the authors analyze and compare two alternative channels for patent acquisition: markets for technology (MFT) and merger and acquisition (M&A) processes. Design/methodology/approach The authors implement two types of analyses, at both patent and firm level. First, the authors perform an econometric analysis to evaluate whether acquired patented technologies differ in their patent bibliographic characteristics with respect to patent-protected technologies that have been developed internally by the examined firms. The authors then investigate the presence of differences in the characteristics of transacted patents acquired in the MFT or by means of M&A activities. Second, the authors take a firm-level perspective and examine the technology acquisition strategies adopted by selected companies to identify the presence of common patterns, industry-driven specificities and firm peculiarities. Findings The authors find that acquired patented technologies are, on average, more complex, of higher technical merit and the corresponding patents show a higher legal robustness. Econometric results reveal the presence of differences between M&A and MFT patents: the latter seem to protect less complex, and thus easier to trade, inventions. The analysis of the patterns of patent acquisitions at the firm level shows the presence of different strategies for the external sourcing of patented technologies, based on whether acquired patents protect core or non-core technology areas of the analyzed firms. Such patterns are discussed in the light of the different streams of the literature on intellectual property (IP) management. Originality/value This paper makes use of a new and comprehensive data set of the US patent transactions that took place between 2002 and 2010. The authors added detailed data on the evolution of the corporate trees of analyzed firms. The paper contributes to the literature on technology acquisitions and MFT by examining the different channels for patented technology acquisitions. The issue represents an emerging area of interest in the field of IP management.


2016 ◽  
Vol 45 (3) ◽  
pp. 577-592 ◽  
Author(s):  
Alejandro Germán Frank ◽  
Marcelo Nogueira Cortimiglia ◽  
José Luis Duarte Ribeiro ◽  
Lindomar Subtil de Oliveira

2016 ◽  
Vol 2 (4) ◽  
pp. 234-241
Author(s):  
Mohammed Al-Shakka ◽  
Ebtesam Abood ◽  
Adel Al-Dhubhany ◽  
Sami Abdo Radman Aldubai ◽  
Khaled Said ◽  
...  

Because of the almost-instant connection with the welfare and well-being of individuals, pharmaceutical industry stands prominently as a very important factor for the improvement and progress of a healthy productive nation. These days, pharmaceutical industry thrives as one of the largest and exponentially expanding global industries. Nonetheless, millions of people in low income developing countries, have to suffer from the fatal consequences of the inaccessibility and non-availability of essential drugs. This is also happening in Yemen, where the pharmaceutical manufacturers sector have to face up to many challenges. The Yemen Drug Company (YEDCO) was founded in 1964 by the Yemeni government as it collaborated with private investors. It was endorsed as a company with the expertise in the medicinal drug marketing. YEDCO started its work by taking in drugs from foreign companies and then locally marketing and distributing them. In 1982, YEDCO built the first medicinal factory for drugs in Sana’a. Since then, seven companies were set up to manufacture medicines in Yemen. The expanding population has led to the need to have more pharmaceutical products. It may be understandable that pharmaceutical manufacturer companies are also hit by the political crisis in the country. Inadequate amount of fuel and raw material as well as low security status were some of the underlying factors behind these ill-effects in Yemen. Imported drugs make up about nearly 90% % of the pharmaceutical market compared to 10% drugs from the domestic market. This situation has led to an additional burden being shouldered by the national economy, where Yemen spends about US$263 million annually on pharmaceutical drugs, in reference to the national Supreme Drugs Authority. Although there is a very quick growth in the population and drugs consumption, the pharmaceutical industry has not been very active, where global pharmaceutical products play their role dominantly on the domestic market. The pharmaceutical production necessitates skilled human resources like university graduates. By contrast, the government and the private sector should also motivate the pharmaceutical industry and make use of the local employment


Sign in / Sign up

Export Citation Format

Share Document